Interpretation of the Keypoints and Updates on National Clinical Guideline for Stroke for the United Kingdom and Ireland (Edition 2023) —Long-Term Management and Secondary Prevention

doi:10.3969/j.issn.1673-5765.2023.12.007

Abstract

Abstract: The recurrence rate of stroke and TIA is high, and recurrent stroke is characterized by high disability rate and high mortality. Timely, scientific and standardized early, secondary prevention can significantly reduce the risk of recurrent events. The national clinical guideline for stroke for the United Kingdom and Ireland (2023 edition) has updated recommendations on the management of risk factors such as blood pressure, lipid metabolic disorder, antiplatelet therapy, anticoagulant therapy, increased physical activity and secondary prevention measures after stroke or TIA.

Key words: Ischemic stroke; Transient ischemic attack; Intracerebral hemorrhage; Risk factor; Secondary prevention

摘要： 卒中和TIA的复发率均较高，且复发性卒中具有高致残率、高死亡率的特点。及时、科学和规范地进行早期二级预防，可大幅降低卒中复发风险。英国国家卒中临床指南2023版对卒中或TIA后血压、脂代谢紊乱、抗血小板治疗、抗凝治疗、增加身体活动等危险因素管理和二级预防措施的推荐意见进行了更新，本文对此进行介绍。

关键词: 缺血性卒中; 短暂性脑缺血发作; 脑出血; 危险因素; 二级预防

WU Na, WANG Liyuan, LI Guangshuo, XIONG Yunyun. Interpretation of the Keypoints and Updates on National Clinical Guideline for Stroke for the United Kingdom and Ireland (Edition 2023) —Long-Term Management and Secondary Prevention [J]. Chinese Journal of Stroke, 2023, 18(12): 1383-1390.

吴娜, 王利圆, 李光硕, 熊云云. 英国国家卒中临床指南2023版要点及解读——长期管理与二级预防[J]. 中国卒中杂志, 2023, 18(12): 1383-1390.

References

[1] KERRY S M，MARKUS H S，KHONG T K，et al. Home blood pressure monitoring with nurse-led telephone support among patients with hypertension and a history of stroke：a community-based randomized controlled trial[J]. CMAJ，2013，185（1）：23-31.
[2] OVAISI S，IBISON J，LEONTOWITSCH M，et al. Stroke patients' perceptions of home blood pressure monitoring：a qualitative study[J/OL]. Br J Gen Pract，2011，61（590）：e604-e610[2023-08-01]. https://doi.org/10.3399/bjgp11X593893.
[3] HANLEY J，FAIRBROTHER P，MCCLOUGHAN L，et al. Qualitative study of telemonitoring of blood glucose and blood pressure in type 2 diabetes[J/OL]. BMJ Open，2015，5（12）：e008896[2023-08-01]. http://dx.doi.org/10.1136/bmjopen-2015-008896.
[4] 王伊龙，陈玮琪，刘欣如，等. 中国脑血管病临床管理指南（第2版）（节选）——第3章脑血管病高危人群管理[J]. 中国卒中杂志，2023，18（8）：898-909.
WANG Y L，CHENG W Q，LIU X R，et al. Chinese stroke association guidelines for clinical management of cerebrovascular diseases（second edition）（excerpt）—chapter three management of patients at hige-risk of cerebrovascular diseases[J]. Chin J Stroke，2023，18（8）：898-909.
[5] KLEINDORFER DO，TOWFIGHI A，CHATURVEDI S，et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2021，52（7）：e364-e467[2023-08-01]. https://doi.org/10.1161/STR.0000000000000375.
[6] AMARENCO P，KIM J S，LABREUCHE J，et al. A comparison of two LDL cholesterol targets after ischemic stroke[J]. N Engl J Med，2020，382（1）：9.
[7] LEE M，CHENG C Y，WU Y L，et al. Association between intensity of low-density lipoprotein cholesterol reduction with statin-based therapies and secondary stroke prevention：a meta-analysis of randomized clinical trials[J]. JAMA Neurol，2022，79（4）：349-358.
[8] 刘丽萍，周宏宇，段婉莹，等. 中国脑血管病临床管理指南（第2版）（节选）——第4章缺血性脑血管病临床管理推荐意见[J]. 中国卒中杂志，2023，18（8）：910-933.
LIU L P，ZHOU H Y，DUAN W Y，et al. Chinese stroke association guidelines for clinical management of cerebrovascular diseases（second edition）（excerpt）—chapter four clinical management of ischaemic cerebrovascular diseases[J]. Chin J Stroke，2023，18（8）：910-933.
[9] RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage（RESTART）：a randomised，open-label trial[J]. Lancet，2019，393（10191）：2613-2623.
[10] 张谦，冀瑞俊，赵萌，等. 中国脑血管病临床管理指南（第2版）（节选）——第5章脑出血临床管理[J]. 中国卒中杂志，2023，18（9）：1014-1023.
ZHANG Q，JI R J，ZHAO M，et al. Chinese stroke association guidelines for clinical management of cerebrovascular diseases（second edition）（excerpt）—chapter five clinical management of intracerebral hemorrhage[J]. Chin J Stroke，2023，18（9）：1014-1023.
[11] PACIARONI M，AGNELLI G，FALOCCI N，et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation：effect of anticoagulation and its timing：the RAF study[J]. Stroke，2015，46（8）：2175-2182.
[12] OLDGREN J，ASBERG S，HIJAZI Z，et al. Early versus delayed non-vitamin k antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation（TIMING）：a registry-based randomized controlled noninferiority study[J]. Circulation，2022，146（14）：1056-1066.
[13] CARROLL J D，SAVER J L，THALER D E，et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke[J]. N Engl J Med，2013，368（12）：1092-1100.
[14] MEIER B，KALESAN B，MATTLE H P，et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism[J]. N Engl J Med，2013，368（12）：1083-1091.
[15] FURLAN A J，REISMAN M，MASSARO J，et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale[J]. N Engl J Med，2012，366（11）：991-999.
[16] LEE P H，SONG J K，KIM J S，et al. Cryptogenic stroke and high-risk patent foramen ovale：The DEFENSE-PFO trial[J]. J Am Coll Cardiol，2018，71（20）：2335-2342.
[17] MAS J L，DERUMEAUX G，GUILLON B，et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J]. N Engl J Med，2017，377（11）：1011-1021.
[18] SØNDERGAARD L，KASNER S E，RHODES J F，et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J]. N Engl J Med，2017，377（11）：1033-1042.
[19] SAVER J L，CARROLL J D，THALER D E，et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke[J]. N Engl J Med，2017，37（11）7：1022-1032.
[20] RODRIGUES M A，SAMARASEKERA N，LERPINIERE C，et al. The edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy：model development and diagnostic test accuracy study[J]. Lancet Neurol，2018，17（3）：232-240.
[21] BIFFI A，KURAMATSU J B，LEASURE A，et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage[J]. Ann Neurol，2017，82（5）：755-765.
[22] ADIB-SAMII P，BRICE G，MARTIN R J，et al. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype：study in 200 consecutively recruited individuals[J]. Stroke，41（4）：630-634.
[23] PETERS N，HOLTMANNSPÖTTER M，OPHERK C，et al. Brain volume changes in CADASIL：a serial MRI study in pure subcortical ischemic vascular disease[J]. Neurology，2006，66（10）：1517-1522.
[24] MANCUSO M，ARNOLD M，BERSANO A，et al. Monogenic cerebral small-vessel diseases：diagnosis and therapy. Consensus recommendations of the European Academy of Neurology[J]. Eur J Neurol，2020，27（6）：909-927.
[25] WILSON D，AMBLER G，LEE K J，et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack：a pooled analysis of individual patient data from cohort studies[J]. Lancet Neurol，2019，18（7）：653-665.